strontium ranelate strontiumii salt ranelic acid medication osteoporosis marketed protelos protos servier studies indicate also slow course osteoarthritis drug unusual increases deposition new bone osteoblasts reduces resorption bone osteoclasts therefore promoted dual action bone agent daba may servier released direct healthcare professional communication stated new restrictions use strontium ranelate place randomised trials shown increased risk myocardial infarction servier states use restricted treatment severe osteoporosis postmenopausal women high risk european pharmacovigilance risk assessment committee prac recommended restriction use strontium ranelate based routine benefitrisk assessment medicine included data showing possible increased risk heart problems including heart february european medicine agency recommended strontium ranelate remain available restrictions relative patients existing heart large study british spanish patients found increased risk venous thromboembolism users strontium ranelate compared servier ceased manufacturing drug drug returned market united kingdom name strontium ranelate strontium ranelate registered prescription drug countries treatment postmenopausal osteoporosis reduce risk vertebral hip fractures united states strontium ranelate approved fda united kingdom strontium ranelate prescribed national health service medicine treatment post menopausal major phase iii clinical studies soti spinal osteoporosis therapeutic intervention tropos treatment peripheral osteoporosis started investigate efficacy strontium ranelate reducing vertebral fractures peripheral fractures including hip fractures years results reported strontium ranelate showed significant reduction vertebral fractures hip fractures compared patients treated efficacy sustained years data years data confirmed strontium ranelate reduce vertebral fractures significantly matter risk factors osteoporotic women include age bone mineral density osteoporotic osteopenia prevalent fractures prevalent fracture prevalent fractures prevalent fractures symptomatic fractures body mass index smoking strontium ranelate shows antifracture efficacy old elderly osteopenic patients strontium ranelate contraindicated hypersensitivity active substance excipients recommended patients severe renal disease ie creatinine clearance mlmin due lack data precaution advised patients increased risk venous thromboembolism vte including patients history vte precaution advised patients phenylketonuria formulations strontium ranelate contain precaution interferes colorimetric measurements calcium blood urine available data show evidence increased cardiovascular risk patients without established current past history ischaemic heart disease peripheral arterial disease cerebrovascular disease without uncontrolled hypertension metaanalysis patients known uncontrolled severe cardiovascular disease strontium ranelate increased risk venous thromboembolism pulmonary embolism serious cardiovascular disorders including myocardial infarction compared placebo versus use restricted uk without severe cardiovascular common side effects include nausea diarrhea headache eczema increase compared placebo group side effects resolved within months occasional severe allergic reactions reported including drug rash eosinophilia systemic symptoms dress according manufacturer strontium ranelate taken hours antacids hours apart food milk derivative products medicinal products containing calcium treatment suspended taking oral tetracycline quinolone antibiotics chelate strontium ion strontium atomic number belongs group ii periodic table elements beneath calcium nucleus nearly size calcium body easily takes strontium incorporates bones tooth enamel place calcium health problem fact provide health benefit example clinical trials drug strontium ranelate found aid bone growth increase bone density lessen vertebral peripheral hip fractures women strontium ranelate antiosteoporotic agent increases bone formation reduces bone resorption resulting rebalance bone turnover favor bone formation similar effects cholinestabilized orthosilicic strontium ranelate stimulates calciumsensing receptors leads differentiation preosteoblast osteoblast increases bone formation strontium ranelate also stimulates osteoblasts secrete osteoprotegerin inhibiting osteoclasts formed preosteoclasts relation rankl system leads decrease bone large international study strontium ranelate efficacy knee osteoarthritis trial sekoia reported drug significantly slowed course knee oa compared placebo doubleblind randomised controlled trial drug reduced knee oa pain symptoms improved function reduced xray detectable cartilage loss shown reductions joint space narrowing three httpsenwikipediaorgwikistrontiumranelate